NDA 209939 · Merck Sharp Dohme
Prevymis
Letermovir · Oral · Cytomegalovirus DNA Terminase Complex Inhibitor
NovelBreakthrough therapyPriority reviewOrphanLast checked: Nov 20, 2026Latest source record: Jan 30, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2017
Nov 8, 2017
Approved uses
5
Original approval plus efficacy supplements
Registered trials
51
13 Phase 3, 16 recruiting
FAERS reports
3,257
2,664 serious, 588 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jan 14, 2026.
PREVYMIS is a CMV DNA terminase complex inhibitor indicated for: Prophylaxis of cytomegalovirus (CMV) infection and disease in adult and pediatric patients 6 months of age and older and weighing at least 6 kg who are CMV-seropositive recipients [R+] of an allogeneic hematopoietic stem cell transplant (HSCT). ( 1.1 ) Prophylaxis of CMV disease in adult and pediatric patients 12 years of age and older and weighing at least 40 kg who are kidney transplant recipients at high risk (Donor CMV seropositive/Recipient CMV seronegative [D+/R-]). ( 1.2 ) 1.1 CMV Prophylaxis in Hematopoietic Stem Cell Transplant (HSCT) Recipients PREVYMIS ® is indicated for prophylaxis of cytomegalovirus (CMV) infection and disease in adult and pediatric patients 6 months of age and older and weighing at least 6 kg who are CMV-seropositive recipients [R+] of an allogeneic hematopoietic stem cell transplant (HSCT). 1.2 CMV Prophylaxis in Kidney Transplant Recipients PREVYMIS is indicated for prophylaxis of CMV disease in adult and pediatric patients 12 years of age and older and weighing at least 40 kg who are kidney transplant recipients at high risk (Donor CMV seropositive/Recipient CMV seronegative [D+/R-]).
Mechanism: PREVYMIS is an antiviral drug against CMV [see Microbiology (12.4) ] .
Therapeutic areas: Infectious disease and vaccines
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Aug 30, 2024 Supplement 13 · Efficacy · priority review OrphanLabelLetter
- Aug 30, 2024 Supplement 16 · Efficacy · priority review OrphanLabelLetter
- Aug 2, 2023 Supplement 11 · Efficacy OrphanLabel
- Jun 5, 2023 Supplement 12 · Efficacy · priority review OrphanLetterLabel
- Nov 8, 2017 Original approval · Type 1 - New Molecular Entity · priority review NovelBreakthrough therapyOrphanLetterLabelReview
2 products under this application
- PREVYMIS · LETERMOVIR 480MG · TABLET, ORAL · Prescription
- PREVYMIS · LETERMOVIR 240MG · TABLET, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Letermovir" as an intervention, any sponsor and status, largest first.
- Letermovir Versus Valganciclovir to Prevent Human Cytomegalovirus Disease in Kidney Transplant Recipients (MK-8228-002)Pivotal-lookingCompleted
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT03443869 · 601 participants · Start May 3, 2018 · Primary completion Apr 5, 2022
Drug: Letermovir; Valganciclovir and 4 more · For: CMV Disease
Sites: Birmingham, Alabama; Los Angeles, California; Sacramento, California · 94 sites in all
- Letermovir (MK-8228) Versus Placebo in the Prevention of Clinically-Significant Cytomegalovirus (CMV) Infection in Adult, CMV-Seropositive Allogeneic Hematopoietic Stem Cell Transplant Recipients (MK-8228-001)Pivotal-lookingCompleted
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT02137772 · 570 participants · Start Jun 6, 2014 · Primary completion Aug 8, 2016
Drug: Letermovir; Placebo · For: Prevention of CMV Infection or Disease
- Efficacy of Extended Letermovir Prophylaxis to Prevent CMV Reactivation in High-Risk Chinese Adults Undergoing Allogeneic HSCTPivotal-lookingRecruiting
The First Affiliated Hospital of Soochow UniversityAcademic, hospital or other
NCT06812598 · 330 participants (planned) · Start Dec 16, 2024 · Primary completion Jun 1, 2026
Drug: Letermovir (0-24w); Letermovir (0-14w) · For: Cytomegalovirus Infections; CMV
Sites: Suzhou, China
- Letermovir vs Valganciclovir in CMV R+ Kidney TransplantNot yet recruiting
Elisabeth KincaideGovernment (non-federal)
NCT07571135 · 300 participants (planned) · Start May 2026 · Primary completion Nov 2028
Drug: Letermovir; Valganciclovir CMV Prophylaxis · For: CMV Infection; CMV; CMV Viremia and 1 more
Sites: San Antonio, Texas
- Efficacy and Safety of Leymovir Versus Valganciclovir in Prevention of Cytomegalovirus Infection and Cytomegalovirus Disease in Chinese Kidney Transplant RecipientsPivotal-lookingRecruiting
First Affiliated Hospital Xi'an Jiaotong UniversityAcademic, hospital or other
NCT07266467 · 290 participants (planned) · Start May 13, 2025 · Primary completion Nov 30, 2026
Drug: Letermovir; Valganciclovir · For: Kidney Transplant
Sites: Xi'an, China
- CMV-specific T Cell Immunity Test Indicated Prophylaxis of Letermovir After All-HSCTPivotal-lookingActive, not recruiting
Ruijin HospitalAcademic, hospital or other
NCT06449586 · 250 participants (planned) · Start Jul 1, 2024 · Primary completion Jun 1, 2026
Drug: Letermovir · For: Hematologic Malignancy
Sites: Wuhan, China; Shanghai, China; Hangzhou, China · 5 sites in all
- Extension of Letermovir (LET) From Day 100 to Day 200 Post-transplant for the Prevention of Cytomegalovirus (CMV) Infection in Hematopoietic Stem Cell Transplant (HSCT) Participants (MK-8228-040)Pivotal-lookingCompleted
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT03930615 · 220 participants · Start Jun 21, 2019 · Primary completion Oct 27, 2021
Drug: Letermovir; Placebo · For: Cytomegalovirus Infection
Sites: Duarte, California; Sacramento, California; Miami, Florida · 32 sites in all
- A Randomized Controlled Trial of Prophylactic Rituximab to Reduce Clinically Significant EBV DNAemia After Allogeneic Hematopoietic Stem Cell TransplantationPivotal-lookingNot yet recruiting
Yang DonglinAcademic, hospital or other
NCT07703657 · 168 participants (planned) · Start Jul 9, 2026 · Primary completion Jul 9, 2027
Drug: Rituximab (Arm A) · For: Allogeneic Hematopoietic Stem Cell Transplantation; Epstein-Barr Virus Reactivation; Clinically Significant EBV DNAemia
Sites: Tianjin, China
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- off label use718
- drug ineffective295
- cytomegalovirus infection reactivation260
- death196
- acute kidney injury178
- cytomegalovirus infection173
- drug interaction166
- product use in unapproved indication165
- pancytopenia153
- drug resistance99
- hospitalisation99
- pyrexia99
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2017 | 1 |
| 2018 | 82 |
| 2019 | 257 |
| 2020 | 272 |
| 2021 | 395 |
| 2022 | 379 |
| 2023 | 413 |
| 2024 | 503 |
| 2025 | 557 |
| 2026 | 398 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Prevymis* (Letermovir)
2024 spending
$120M
Beneficiaries
3,884
16,441 claims
Per beneficiary
$31,012
$252.09 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $28,098,445 |
| 2021 | $38,109,251 |
| 2022 | $48,827,212 |
| 2023 | $73,949,062 |
| 2024 | $120,450,531 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation.
Marty FM, Ljungman P, Chemaly RF, et al. · N Engl J Med 2017 · Clinical Trial, Phase III, Multicenter Study
- Efficacy and safety of extended duration letermovir prophylaxis in recipients of haematopoietic stem-cell transplantation at risk of cytomegalovirus infection: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Russo D, Schmitt M, Pilorge S, et al. · Lancet Haematol 2024 · Randomized Controlled Trial, Multicenter Study
- Antiviral prophylaxis for cytomegalovirus infection in allogeneic hematopoietic cell transplantation.
Chen K, Cheng MP, Hammond SP, et al. · Blood Adv 2018 · Research Support, Non-U.S. Gov't, Systematic Review
- Antiviral Agents for Preventing Cytomegalovirus Disease in Recipients of Hematopoietic Cell Transplantation.
Jaing TH, Wang YL, Chiu CC · Viruses 2024 · Systematic Review
- Cytomegalovirus prophylaxis with letermovir in pediatric (birth to <18 years of age) hematopoietic cell transplant recipients: pharmacokinetics, efficacy, and safety results of a Phase 2b study.
Groll AH, Danziger-Isakov L, Gefen A, et al. · Antimicrob Agents Chemother 2025 · Clinical Trial, Phase II
- Pharmacokinetics, Safety, and Efficacy of Letermovir for Cytomegalovirus Prophylaxis in Adolescent Hematopoietic Cell Transplantation Recipients.
Groll AH, Schulte JH, Antmen AB, et al. · Pediatr Infect Dis J 2024 · Clinical Trial, Phase II, Multicenter Study
Sponsor: Merck & Co.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.